ANCA ZGURA, LAURENTIA GALES, BOGDAN HAINEALA, ELVIRA BRATILA, CLAUDIA MEHEDINTU, RAMONA ILEANA BARAC, COSTIN BERCEANU, CRISTINA VERONICA ANDREESCU, LACRAMIOARA AURELIA BRINDUSE, ALEC IONESCU, RODICA ANGHEL IMMUNE EFFECTS OF TRANSTUZUMAB IN HER2 POSITIVE BREAST CANCER
The immune system could mediate the antitumor activity of several anticancer treatments. Several chemotherapy compounds, including anthracyclines and oxaliplatin, induce immunogenic cell death that in turn activates the antitumor immune response. Trastuzumab induces antibody-dependant cell-mediated cytotoxicity. On the basis of this background, immune markers have recently been the focus of intense translational research to predict and monitor the efficacy of treatments. Gene expression arrays and immunohistochemistry have assessed immune activation and infiltration by macrophages, natural killer, and T and B lymphocytes. In this paper we present the results of a study that included 22 patients diagnosed with Her2 positive breast cancer undergoing treatment with Transtuzumab.
Keywords: chemotherapy , trastuzumab, cytotoxicity, T and B lymphocytes